{"entity":{"id":"lysa","kind":"company","name":"LYSA (The Lymphoma Study Association)","aka":["LYSA","GELA","Groupe d'Etude des Lymphomes de l'Adulte","GOELAMS","LYSARC"],"tldr":"The French-Belgian lymphoma group, successor to GELA, whose LNH-98.5 trial made R-CHOP the standard for diffuse large B-cell lymphoma.","summary":"LYSA was formed in 2012 by merging GELA (founded 1984) and GOELAMS; LYSARC is its academic research organisation. GELA's LNH-98.5 was the trial that added rituximab to CHOP and changed the outcome of DLBCL worldwide, and PRIMA established rituximab maintenance in follicular lymphoma. LYSA co-ran POLARIX (polatuzumab-R-CHP) and leads trials of bispecific antibodies, CAR-T sequencing and PET-guided therapy across France, Belgium and Portugal. It maintains a national lymphoma pathology review network (Lymphopath) and the REALYSA real-world cohort.","asOf":"2026-09-09","links":[{"label":"LYSA","url":"https://www.lysa-lymphoma.org"}],"tags":["cooperative-group"],"related":["glofitamab","axicabtagene-ciloleucel"],"cancers":["dlbcl","hodgkin-lymphoma"],"sections":[],"technologies":["monoclonal-antibody","bispecific-antibody","car-t","fdg-pet"],"targets":[],"drugs":[],"companies":["ielsg","german-lymphoma-alliance"],"institutions":["institut-curie","centre-henri-becquerel"],"pathways":[],"terms":[],"trials":["prima","polarix"],"people":["steven-le-gouill","franck-morschhauser","herve-tilly"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["LNH-98.5 (R-CHOP)","PRIMA (rituximab maintenance)","POLARIX (with Roche)","REALYSA cohort and Lymphopath"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Pierre-Bénite (Lyon)","country":"FR","companyType":"cooperative-group","website":"https://www.lysa-lymphoma.org","founded":2012,"investors":[],"funding":[]},"route":"/companies/lysa/","neighbours":{"drug":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"company":[{"id":"german-lymphoma-alliance","kind":"company","name":"German Lymphoma Alliance","route":"/companies/german-lymphoma-alliance/"},{"id":"ielsg","kind":"company","name":"International Extranodal Lymphoma Study Group","route":"/companies/ielsg/"}],"institution":[{"id":"centre-henri-becquerel","kind":"institution","name":"Centre Henri Becquerel","route":"/institutions/centre-henri-becquerel/"},{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/"}],"trial":[{"id":"ahl2011","kind":"trial","name":"AHL2011","route":"/trials/ahl2011/"},{"id":"mosun-len-mzl","kind":"trial","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","route":"/trials/mosun-len-mzl/"},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/"},{"id":"prima-follicular","kind":"trial","name":"PRIMA","route":"/trials/prima-follicular/"},{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/"},{"id":"remarc","kind":"trial","name":"REMARC","route":"/trials/remarc/"}],"person":[{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/"},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/"},{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","route":"/people/herve-tilly/"},{"id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","route":"/people/steven-le-gouill/"}],"paper":[{"id":"paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017","kind":"paper","name":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP","route":"/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/"},{"id":"paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019","kind":"paper","name":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","route":"/key-papers/paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019/"},{"id":"paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017","kind":"paper","name":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","route":"/key-papers/paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017/"},{"id":"paper-prima-rituximab-maintenance-follicular-lancet-2011","kind":"paper","name":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","route":"/key-papers/paper-prima-rituximab-maintenance-follicular-lancet-2011/"},{"id":"paper-prima-final-rituximab-maintenance-follicular-jco-2019","kind":"paper","name":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","route":"/key-papers/paper-prima-final-rituximab-maintenance-follicular-jco-2019/"}]}}